Dose-intense etoposideacyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Dose-intense etoposideacyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determi...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2013-08, Vol.37 (8), p.872-876
Main Authors: Trifilio, Steven, Zhou, Zheng, Altman, Jessica, Frankfurt, Olga, Pantiru, Mihaela, Mehta, Jayesh
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dose-intense etoposideacyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.
ISSN:0145-2126
DOI:10.1016/j.leukres.2013.05.006